These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

303 related items for PubMed ID: 27072400

  • 1. A novel EGR-1 dependent mechanism for YB-1 modulation of paclitaxel response in a triple negative breast cancer cell line.
    Lasham A, Mehta SY, Fitzgerald SJ, Woolley AG, Hearn JI, Hurley DG, Ruza I, Algie M, Shelling AN, Braithwaite AW, Print CG.
    Int J Cancer; 2016 Sep 01; 139(5):1157-70. PubMed ID: 27072400
    [Abstract] [Full Text] [Related]

  • 2. New Insights in Gene Expression Alteration as Effect of Paclitaxel Drug Resistance in Triple Negative Breast Cancer Cells.
    Jurj A, Pop LA, Zanoaga O, Ciocan-Cârtiţă CA, Cojocneanu R, Moldovan C, Raduly L, Pop-Bica C, Trif M, Irimie A, Berindan-Neagoe I, Braicu C.
    Cell Physiol Biochem; 2020 Jul 04; 54(4):648-664. PubMed ID: 32619350
    [Abstract] [Full Text] [Related]

  • 3. BRCA1-IRIS inactivation overcomes paclitaxel resistance in triple negative breast cancers.
    Blanchard Z, Paul BT, Craft B, ElShamy WM.
    Breast Cancer Res; 2015 Jan 13; 17(1):5. PubMed ID: 25583261
    [Abstract] [Full Text] [Related]

  • 4. TNFSF13 upregulation confers chemotherapeutic resistance via triggering autophagy initiation in triple-negative breast cancer.
    Lin HY, Kuei CH, Lee HH, Lin CH, Chen YL, Chen CL, Lin YF.
    J Mol Med (Berl); 2020 Sep 13; 98(9):1255-1267. PubMed ID: 32671412
    [Abstract] [Full Text] [Related]

  • 5. Increased nuclear localization of transcription factor Y-box binding protein 1 accompanied by up-regulation of P-glycoprotein in breast cancer pretreated with paclitaxel.
    Fujita T, Ito K, Izumi H, Kimura M, Sano M, Nakagomi H, Maeno K, Hama Y, Shingu K, Tsuchiya S, Kohno K, Fujimori M.
    Clin Cancer Res; 2005 Dec 15; 11(24 Pt 1):8837-44. PubMed ID: 16361573
    [Abstract] [Full Text] [Related]

  • 6. Cyr61 and YB-1 are novel interacting partners of uPAR and elevate the malignancy of triple-negative breast cancer.
    Huber MC, Falkenberg N, Hauck SM, Priller M, Braselmann H, Feuchtinger A, Walch A, Schmitt M, Aubele M.
    Oncotarget; 2016 Jul 12; 7(28):44062-44075. PubMed ID: 27286449
    [Abstract] [Full Text] [Related]

  • 7. CELF6 modulates triple-negative breast cancer progression by regulating the stability of FBP1 mRNA.
    Yang X, Zhao L, Pei J, Wang Z, Zhang J, Wang B.
    Breast Cancer Res Treat; 2020 Aug 12; 183(1):71-82. PubMed ID: 32601971
    [Abstract] [Full Text] [Related]

  • 8. Luteolin is a novel p90 ribosomal S6 kinase (RSK) inhibitor that suppresses Notch4 signaling by blocking the activation of Y-box binding protein-1 (YB-1).
    Reipas KM, Law JH, Couto N, Islam S, Li Y, Li H, Cherkasov A, Jung K, Cheema AS, Jones SJ, Hassell JA, Dunn SE.
    Oncotarget; 2013 Feb 12; 4(2):329-45. PubMed ID: 23593654
    [Abstract] [Full Text] [Related]

  • 9. Sulforaphene inhibits triple negative breast cancer through activating tumor suppressor Egr1.
    Yang M, Teng W, Qu Y, Wang H, Yuan Q.
    Breast Cancer Res Treat; 2016 Jul 12; 158(2):277-86. PubMed ID: 27377973
    [Abstract] [Full Text] [Related]

  • 10. Targeting EGFR of triple-negative breast cancer enhances the therapeutic efficacy of paclitaxel- and cetuximab-conjugated nanodiamond nanocomposite.
    Liao WS, Ho Y, Lin YW, Naveen Raj E, Liu KK, Chen C, Zhou XZ, Lu KP, Chao JI.
    Acta Biomater; 2019 Mar 01; 86():395-405. PubMed ID: 30660004
    [Abstract] [Full Text] [Related]

  • 11. MicroRNA-101 inhibits cell progression and increases paclitaxel sensitivity by suppressing MCL-1 expression in human triple-negative breast cancer.
    Liu X, Tang H, Chen J, Song C, Yang L, Liu P, Wang N, Xie X, Lin X, Xie X.
    Oncotarget; 2015 Aug 21; 6(24):20070-83. PubMed ID: 26036638
    [Abstract] [Full Text] [Related]

  • 12. circGFRA1 affects the sensitivity of triple-negative breast cancer cells to paclitaxel via the miR-361-5p/TLR4 pathway.
    Zheng SR, Huang QD, Zheng ZH, Zhang ZT, Guo GL.
    J Biochem; 2021 Jul 03; 169(5):601-611. PubMed ID: 33481008
    [Abstract] [Full Text] [Related]

  • 13. CCAAT enhancer binding protein delta activates vesicle associated membrane protein 3 transcription to enhance chemoresistance and extracellular PD-L1 expression in triple-negative breast cancer.
    Zhao Y, Yu Y, Li X, Guo A.
    J Exp Clin Cancer Res; 2024 Apr 16; 43(1):115. PubMed ID: 38627816
    [Abstract] [Full Text] [Related]

  • 14. CXCL8 Facilitates the Survival and Paclitaxel-Resistance of Triple-Negative Breast Cancers.
    Yi M, Peng C, Xia B, Gan L.
    Clin Breast Cancer; 2022 Feb 16; 22(2):e191-e198. PubMed ID: 34284965
    [Abstract] [Full Text] [Related]

  • 15. Knockdown of lncRNA H19 restores chemo-sensitivity in paclitaxel-resistant triple-negative breast cancer through triggering apoptosis and regulating Akt signaling pathway.
    Han J, Han B, Wu X, Hao J, Dong X, Shen Q, Pang H.
    Toxicol Appl Pharmacol; 2018 Nov 15; 359():55-61. PubMed ID: 30244121
    [Abstract] [Full Text] [Related]

  • 16. SYTL4 downregulates microtubule stability and confers paclitaxel resistance in triple-negative breast cancer.
    Liu XY, Jiang W, Ma D, Ge LP, Yang YS, Gou ZC, Xu XE, Shao ZM, Jiang YZ.
    Theranostics; 2020 Nov 15; 10(24):10940-10956. PubMed ID: 33042263
    [Abstract] [Full Text] [Related]

  • 17. Cellular uptake mechanism and comparative evaluation of antineoplastic effects of paclitaxel-cholesterol lipid emulsion on triple-negative and non-triple-negative breast cancer cell lines.
    Ye J, Xia X, Dong W, Hao H, Meng L, Yang Y, Wang R, Lyu Y, Liu Y.
    Int J Nanomedicine; 2016 Nov 15; 11():4125-40. PubMed ID: 27601899
    [Abstract] [Full Text] [Related]

  • 18. Interleukin-22 promotes triple negative breast cancer cells migration and paclitaxel resistance through JAK-STAT3/MAPKs/AKT signaling pathways.
    Wang S, Yao Y, Yao M, Fu P, Wang W.
    Biochem Biophys Res Commun; 2018 Sep 10; 503(3):1605-1609. PubMed ID: 30072097
    [Abstract] [Full Text] [Related]

  • 19. Long non-coding RNA LINC-PINT attenuates paclitaxel resistance in triple-negative breast cancer cells via targeting the RNA-binding protein NONO.
    Chen J, Zhu M, Zou L, Xia J, Huang J, Deng Q, Xu R.
    Acta Biochim Biophys Sin (Shanghai); 2020 Aug 05; 52(8):801-809. PubMed ID: 32632453
    [Abstract] [Full Text] [Related]

  • 20. MicroRNA-5195-3p enhances the chemosensitivity of triple-negative breast cancer to paclitaxel by downregulating EIF4A2.
    Liu M, Gong C, Xu R, Chen Y, Wang X.
    Cell Mol Biol Lett; 2019 Aug 05; 24():47. PubMed ID: 31308851
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 16.